Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | GCGR | P47871 | 4/20 | 0.54 |
| ▸ | GIPR | P48546 | 4/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608651 | 0.88 | ROCK1 (0.60) | ENPP2ALOX5GCGRGIPRROCK1 | |
| SCHEMBL3606071 | 0.86 | ENPP2 (0.61) | ENPP2ALOX5GCGRGIPRHDAC3 | |
| SCHEMBL3618001 | 0.84 | ENPP2 (0.59) | ENPP2PPARAPPARDROCK1ROCK2 | |
| SCHEMBL15499905 | 0.81 | HDAC3 (0.54) | ALOX5GCGRGIPRHDAC3HDAC4 | |
| SCHEMBL3613941 | 0.81 | RHOC (0.60) | ENPP2ALOX5GCGRGIPRROCK1 | |
| SCHEMBL3613478 | 0.81 | ENPP2 (0.62) | ENPP2ROCK1ROCK2MAPTSMN1; SMN2 | |
| SCHEMBL3603763 | 0.80 | ENPP2 (0.57) | ENPP2GCGRGIPRROCK1ROCK2 | |
| SCHEMBL3612025 | 0.80 | ENPP2 (0.62) | ENPP2GCGRGIPRROCK1ROCK2 | |
| SCHEMBL3603603 | 0.80 | ENPP2 (0.61) | ENPP2HDAC4ROCK1ROCK2MAPT | |
| SCHEMBL3607656 | 0.80 | ENPP2 (0.64) | ENPP2HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | claimed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | claimed |
| EP-1928848-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | Apogee Biothechnology Corporation (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007019251-A9 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORP (US) | 2007-04-19 | — | — | WO | claimed |
| WO-2007019251-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-15 | — | — | WO | claimed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | claimed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1928848-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | Apogee Biothechnology Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007019251-A9 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORP (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007019251-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | ENPP2 42/4885ALOX5 428/4885GCGR 2890/4885 |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | ENPP2 80/4885ALOX5 254/4885GCGR 2302/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | ENPP2 42/4885ALOX5 416/4885GCGR 2806/4885 |
| US-20100048571-A1 | Organic Compounds | XIAP, BAX, MCL1 | ENPP2 2557/4885ALOX5 3423/4885GCGR 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.